New analysis suggests GLP-1 weight loss treatments including Mounjaro and Wegovy have reached three million UK adults, with consulting firm PwC forecasting that number could more than double to seven million as pill-based alternatives and new medicines approach availability. Worldpanel data cited by Grocery Gazette shows GLP-1 users now live in more than six in every hundred British households — and retailers are already redesigning their products in response.
Three million UK adults are now estimated to use GLP-1 medicines, according to new analysis from PwC — a figure that shows just how rapidly treatments such as Mounjaro and Wegovy have moved into the mainstream.
The scale of the GLP-1 revolution in the UK is coming into sharper focus. According to analysis reported by Grocery Gazette and attributed to PwC, approximately three million UK adults are currently using GLP-1 medicines such as Mounjaro (tirzepatide) and Wegovy (semaglutide). That figure, if accurate, would represent a transformation in British healthcare that has happened remarkably quickly — and new data suggests the pace is still accelerating.
Worldpanel figures cited in the same reporting show that 6.3% of British households now contain at least one GLP-1 user, compared with 4.1% in 2025 and 2.3% the year before. That near-tripling of household penetration over two years reflects a rapidly expanding market, including both NHS prescribing and substantial private access, with Mounjaro in particular becoming widely available through online clinics and high street pharmacies.
What PwC’s Seven Million Forecast Actually Means
According to the PwC analysis, the number of people using GLP-1 medicines in the UK could rise from approximately three million today to around seven million — roughly 13% of the adult population. PwC expects pill-based GLP-1 treatments to be an important driver of further growth because they remove one of the main barriers for some potential users: a reluctance to self-inject.
That part of the market has already moved quickly. In June 2026, the MHRA authorised an oral semaglutide tablet under the Wegovy brand for weight loss and weight management, making it the first GLP-1 tablet authorised for weight management in the UK.
Then, in August 2026, the MHRA authorised orforglipron, under the brand name Foundayo, for weight management and type 2 diabetes. Both are prescription-only medicines, and regulatory approval does not automatically mean a treatment is available through the NHS.
The arrival of oral GLP-1 medicines is significant because it potentially opens this category to people who might consider treatment but have been put off by injections. You can read more about the Wegovy pill in the UK and what its approval could mean for patients.
Retatrutide, a triple hormone receptor agonist also in development by Eli Lilly, has shown particularly strong weight loss results in clinical trials and is among the treatments expected to shape the next phase of this market. Unlike the newly authorised oral treatments, retatrutide is not currently MHRA-authorised for weight management in the UK. Our retatrutide UK guide covers its current development status in detail.
How GLP-1 Users Are Already Changing What Britain Buys
The retail data emerging from this analysis is striking in its consistency. According to Grocery Gazette’s reporting, GLP-1 users consistently shop with smaller baskets, spend less on snacks and alcohol, and shift their purchases toward products perceived as healthier. This is not entirely surprising — reduced appetite is a well-documented effect of GLP-1 medicines — but the aggregate scale of these changes is now large enough to register clearly in supermarket and food manufacturer data.
Major retailers and food companies are said to be responding by reconsidering portion sizes, pack formats and new product development. Smaller pack sizes, reformulated products and a greater emphasis on protein content are among the reported adjustments being explored. This is a commercial response to a genuine shift in consumer behaviour, though it also reflects an assumption among retailers that GLP-1 adoption will continue to rise rather than plateau.
If anything approaching 13% of UK adults were eventually using a GLP-1 medicine, the implications for Britain’s food and retail industries would be considerable. The industry’s interest in changing shopping habits is therefore understandable.
The NHS Picture
Current NHS access to GLP-1 weight loss treatments remains more restricted than private access. Wegovy injections are available to eligible patients through NHS weight-management pathways, while Mounjaro has also been recommended for weight management and is being introduced through a phased NHS rollout.
The arrival of oral treatments adds another dimension. MHRA authorisation means a medicine has been approved for use in the UK, but it does not automatically make that treatment routinely available through the NHS. NHS access is subject to separate assessment, eligibility and commissioning decisions.
The pace of NHS rollout has not matched the growth of the private market, which is one reason why the estimated three million current GLP-1 users are likely to include a substantial proportion of people paying privately.
If use does rise towards seven million, the implications for NHS capacity, prescribing budgets and weight-management services would be considerable. How much of that demand would ultimately be met by the NHS — and how much would remain within the private market — is still uncertain.
What This Means For UK Patients
If you are currently using Mounjaro, Wegovy or another GLP-1 treatment, this data puts your experience in a broader context: according to PwC’s estimate, around one in twenty UK adults may now be using a GLP-1 medicine.
The arrival of pill-based alternatives could broaden that market considerably. For people who have previously been reluctant to use an injectable treatment, an oral option removes an obvious barrier — although eligibility, prescribing decisions, availability and cost will still determine who can actually access these medicines.
The forecast rise towards seven million users should be read as a scenario, not a guarantee. It depends on how quickly oral medicines become widely available, NHS funding decisions, private pricing and how many people who currently avoid injections would consider taking a tablet instead. Each of those variables remains uncertain.
That said, the direction of travel — more treatments, more users and potentially broader access — is increasingly clear.
For patients currently managing costs privately, competition between providers makes comparing prices increasingly important. Our Mounjaro price comparison tracks current private clinic pricing across the UK.
On the retail changes: if you find your appetite and shopping habits have genuinely shifted since starting treatment, you are not imagining it — and the supermarkets have noticed too. Reduced appetite can lead to smaller portion sizes and less impulsive snacking for some GLP-1 users, and these individual changes are now occurring on a scale large enough to become visible in national consumer data.
Frequently Asked Questions
Are three million UK adults really using GLP-1 medicines?
This figure comes from PwC analysis rather than an official NHS count. It should therefore be understood as a research estimate rather than a precise national total confirmed by NHS England or the MHRA.
The estimate is nevertheless significant because it illustrates just how quickly the UK market for medicines such as Mounjaro and Wegovy has expanded.
Could seven million UK adults really be using GLP-1 treatments?
PwC’s analysis suggests the number of current users could rise from approximately three million to around seven million, equivalent to roughly 13% of UK adults.
The projection is linked particularly to the growth of oral GLP-1 medicines, which could make treatment more attractive to people who do not want to inject themselves.
It is a forecast rather than a guarantee, and actual uptake will depend on factors including availability, eligibility, NHS access and private treatment costs.
Are GLP-1 weight loss pills approved in the UK?
Yes. The MHRA authorised an oral semaglutide tablet under the Wegovy brand for weight loss and weight management in June 2026, making it the first GLP-1 tablet authorised for weight management in the UK.
In August 2026, the MHRA also authorised orforglipron, branded Foundayo, for weight management and type 2 diabetes.
Both are prescription-only medicines.
Does MHRA approval mean the new GLP-1 tablets are available on the NHS?
No. Regulatory authorisation and NHS availability are separate processes.
MHRA authorisation means a medicine has met the required standards for quality, safety and effectiveness for its authorised use. Decisions about routine NHS access involve separate assessment, eligibility and commissioning arrangements.
Patients should check current NHS guidance or speak to their healthcare professional for the latest information on availability.
Will supermarkets actually change their products because of GLP-1 use?
Several major food manufacturers and retailers have publicly said they are studying GLP-1 users’ shopping behaviour and factoring it into product development. Whether this leads to significant product changes in UK supermarkets depends on how sustained and large-scale the shift in consumer behaviour proves to be.
Smaller portions, different pack sizes and a greater emphasis on protein-rich products are among the areas attracting attention as manufacturers respond to changing consumer habits.
Does being on Mounjaro or Wegovy mean I will automatically eat less?
Reduced appetite is a well-documented effect of GLP-1 medicines, but the degree varies between individuals. These medicines affect hormones involved in appetite and blood sugar regulation, but individual responses depend on factors including the medicine, dose, length of treatment and personal circumstances.
Any concerns about appetite, side effects or treatment should be discussed with your prescribing healthcare professional.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
